Clinical Trials · NCT06072963
COMMETS- Combination MCI Metabolic Syndrome
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Rutgers, The State University of New Jersey
- Enrollment
- 80
- Start date
- Jan 2024
- Locations
- 1 site, Israel
- Primary endpoint
- Cognitive change - The effect of the combination of Semaglutide and intranasal insulin on cognitive functioning.